(NP (NP (NN Proliferation) (NN index)) (PP (IN as) (NP (NP (DT a) (JJ prognostic) (NN marker)) (PP (IN in) (NP (NN breast) (NN cancer))))) (. .))
(NP (NN BACKGROUND) (. .))
(S (NP-SBJ-6 (NP (DT The) (JJ proliferative) (NN activity)) (PP (IN of) (NP (NNS tumors)))) (VP (VBZ has) (VP (VBN been) (VP (ADVP (RB extensively)) (VBN investigated) (NP (-NONE- *-6)) (PP (IN with) (NP (NP (JJ different) (NNS approaches)) (, ,) (SBAR (WHPP-7 (IN among) (WHNP (WDT which))) (S (NP-SBJ (NP (DT the) (NN use)) (PP (IN of) (NP (DT the) (JJ monoclonal) (NN antibody) (NN Ki-67)))) (VP (VBZ represents) (NP (NP (DT an) (ADJP-COOD (ADJP (JJ easy)) (CC and) (ADJP (JJ reliable))) (NN means)) (PP (IN of) (S (NP-SBJ (-NONE- *)) (VP (VBG assessing) (NP (NN cell) (NN proliferation)))))) (PP (-NONE- *T*-7)))))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (, ,) (S-COOD (S (NP-SBJ-8 (NP (DT the) (JJ proliferative) (NN activity)) (PP (IN of) (NP (CD 129) (JJ primary) (NN breast) (NNS cancers)))) (VP (VBD was) (VP (VBN investigated) (NP (-NONE- *-8))))) (, ,) (CC and) (S (NP-SBJ-105 (DT the) (NNS results)) (VP (VBD were) (VP (JJ related) (NP (-NONE- *-105)) (PP (TO to) (NP (NN prognosis))))))) (. .))
(NP (NNS METHODS) (. .))
(S (NP-SBJ-10 (NP (NN Tumor) (NNS samples)) (, ,) (VP (VBN obtained) (NP (-NONE- *)) (PP (IN from) (NP (NP (CD 129) (NNS patients)) (SBAR (WHNP-11 (WP who)) (S (NP-SBJ (-NONE- *T*-11)) (VP (VBD underwent) (NP (NN surgery)) (PP-TMP (IN between) (NP-COOD (NP (NNP January) (CD 1987)) (CC and) (NP (NNP December) (CD 1988)))))))))) (, ,)) (VP (VBD were) (VP (VBN processed) (NP (-NONE- *-10)) (PP (IN for) (NP (VBG staining))) (PP (IN by) (NP (NP (DT an) (JJ immunohistochemical) (NN procedure)) (PRN (-LRB- -LRB-) (NP (NN avidin-biotin) (NN complex)) (-RRB- -RRB-)))))) (. .))
(S (NP-SBJ (NP (DT The) (JJ median) (NN time)) (PP (IN of) (NP (NN observation)))) (VP (VBD was) (NP-PRD (CD 42) (NNS months)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN range)) (, ,) (NP-PRD (QP (CD 31-55)) (NNS months))) (-RRB- -RRB-))) (. .))
(S (NP-SBJ-12 (NP (JJ Life-table) (NN analysis)) (PRN (-LRB- -LRB-) (NP (NN Mantel-Cox)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN used) (NP-110 (-NONE- *-12)) (S (NP-SBJ (-NONE- *-110)) (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN probability)) (PP (IN of) (NP-COOD (NP (NP (JJ disease-free) (NN survival)) (PRN (-LRB- -LRB-) (NP (NN DFS)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ overall) (NN survival)) (PRN (-LRB- -LRB-) (NP (NN OS)) (-RRB- -RRB-))))))))))) (. .))
(NP (NNS RESULTS) (. .))
(S (NP-SBJ-14 (NP (NNS Tumors)) (PP (IN with) (NP (NP (JJ high) (NN Ki-67) (NN proliferation) (NNS indices)) (PRN (-LRB- -LRB-) (NP (QP (JJR &gt;) (CD 20)) (NN %)) (-RRB- -RRB-))))) (VP (VBD were) (VP (VBN associated) (NP-101 (-NONE- *-14)) (PP (IN with) (NP (NP (DT a) (JJR higher) (JJ 4-year) (NN probability)) (PP (IN of) (NP-COOD (NP (NP (NP (NN relapse)) (PP (IN of) (NP (NN disease)))) (PRN (-LRB- -LRB-) (NP-COOD (NP (CD 55.3) (NN %)) (CC versus) (NP (CD 79.1) (NN %))) (: ;) (S (NP-SBJ (NN P)) (VP (JJ =) (NP-PRD (CD 0.003)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN death)) (PRN (-LRB- -LRB-) (NP-COOD (NP (CD 71) (NN %)) (CC versus) (NP (CD 95.6) (NN %))) (: ;) (S (NP-SBJ (NN P)) (VP (JJ =) (NP-PRD (CD 0.00005)))) (-RRB- -RRB-))))))) (SBAR-TMP (WHADVP-15 (WRB when)) (S (NP-SBJ-102 (-NONE- *-101)) (VP (VBN compared) (NP (-NONE- *-102)) (PP (IN with) (NP (NP (NNS tumors)) (PP (IN with) (NP (JJ low) (NN Ki-67) (NNS values))))) (ADVP (-NONE- *T*-15))))))) (. .))
(S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (DT this) (JJ proliferative) (NN parameter)) (VP (VBD maintained) (NP (PRP$ its) (JJ prognostic) (NN significance)) (SBAR-TMP (WHADVP-16 (WRB when)) (S (NP-SBJ-17 (DT the) (NNS patients)) (VP (VBD were) (VP (VBN stratified) (NP (-NONE- *-17)) (PP (VBG according) (PP (TO to) (NP-COOD (NP (NN lymph) (NN node) (NN involvement)) (, ,) (NP (JJ menopausal) (NN status)) (, ,) (CC and) (NP (JJ nuclear) (NN estrogen) (NN receptor) (NN content))))) (ADVP (-NONE- *T*-16))))))) (. .))
(NP (NNS CONCLUSIONS) (. .))
(S (NP-SBJ-18 (NP (NN Tumor) (JJ proliferative) (NN activity)) (SBAR (IN as) (S (NP-SBJ-19 (-NONE- *)) (VP (VBN evaluated) (NP (-NONE- *-19)) (PP (IN by) (NP (DT the) (JJ monoclonal) (NN antibody) (NN Ki-67))))))) (VP (VBZ seems) (S (NP-SBJ (-NONE- *-18)) (VP (TO to) (VP (VB be) (NP-PRD (NP (DT an) (JJ effective) (NN indicator)) (PP (IN of) (NP (NP (NN prognosis)) (PP (IN in) (NP (NN breast) (NN cancer))))) (PP (IN for) (NP-COOD (NP (NN DFS)) (CC and) (NP (NN OS))))))))) (. .))
